biotech / news / / Devdiscourse
Sales of Entresto sank 42% to $1.31 billion after its U.S. patents expired last year.
Novartis' Entresto sales fell 42% to $1.31 billion, below analyst expectations of $1.37 billion.
KEY POINTS
- Novartis expects a $4 billion sales decline this year due to Entresto's U.S. generic competition.
- Patent expiries for Cosentyx, Kesimpta, and Kisqali are set for early 2030s, increasing future risk.
- Novartis is relying on Kisqali and Kesimpta growth to offset declining Entresto revenues.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →